Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Moodys
McKesson
Colorcon
Harvard Business School

Last Updated: November 17, 2019

DrugPatentWatch Database Preview

Litigation Details for Silvergate Pharmaceuticals Inc. v. Bionpharma Inc. (D. Del. 2016)

See Plans and Pricing

« Back to Dashboard

Silvergate Pharmaceuticals Inc. v. Bionpharma Inc. (D. Del. 2016)

Docket   Start Trial Date Filed 2016-09-28
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To
Jury Demand None Referred To
Parties BIONPHARMA INC.; SILVERGATE PHARMACEUTICALS INC.
Patents 8,568,747; 8,778,366
Attorneys Andrew M. Alul; Anjali D. Deshmukh; Brian P. Murray; David M. Hanna; Douglas H. Carsten; Jack B. Blumenfeld; Kenneth Laurence Dorsney; Kristina M. Hanson; Megan Elizabeth Dellinger; Natalie Morgan; Nathaniel R. Scharn; Richard T. Ruzich; Stephen R. Auten; Wendy L. Devine
Firms Morris, Nichols, Arsht & Tunnell
Link to Docket External link to docket
Small Molecule Drugs cited in Silvergate Pharmaceuticals Inc. v. Bionpharma Inc.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Silvergate Pharmaceuticals Inc. v. Bionpharma Inc. (D. Del. 2016)

Date Filed Document No. Description Snippet Link To Document
2018-01-17 147 pertaining to U.S. Patent Nos. 8,568,747 (the “’747 patent”) and 8,778,366 (the “’366 patent”) (collectively…matter of the Patents-in-Suit or any patents or patent applications related to the Patents-in-Suit ….” …Fed. Cir. 2007). The faces of the patents-in-suit, and the U.S. Patent and Trademark Office’s electronic… Production of Assignments and Licenses of the Patents-In-Suit - filed by Bionpharma Inc.. (Attachments… PRODUCTION OF ASSIGNMENTS AND LICENSES OF THE PATENTS-IN-SUIT Defendant Bionpharma Inc. (“Defendant External link to document
2018-04-03 198 U.S. Patent No. 8,568,747 (“the ’747 Patent”) and U.S. Patent No. 8,778,366 (“the ’366 Patent”), has…include a third patent. While this patent will be litigated with the ’747 and the ’366 Patents, because claim…address only Column 19 of the ’747 Patent, the ’747 Patent and ’366 Patent share a common specification. I…of seven terms contained in the ’747 Patent and the ’366 Patent’s claims.2 1 On May 18, 2017, Chief… before the expiration of the ’747 Patent. The ’366 Patent was issued to the same inventors on External link to document
2016-09-28 4 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,568,747 B1;. (dmp, ) (Entered…28 September 2016 1:16-cv-00876 830 Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Merck
Dow
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.